CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
Theralase Technologies (TLTFF) announced it will present new preclinical research on radiation-activated Rutherrin® at the ASTRO 2025 67th Annual Meeting in San Francisco. The study evaluates Rutherrin®, a ruthenium-based drug formulated with human transferrin, against radiation alone in treating cancer.
The research explores Rutherrin's dual cancer-fighting mechanism: immediate cytotoxicity through Reactive Oxygen Species generation and sustained immune response through Immunogenic Cell Death. Key aspects to be presented include tumor targeting, blood-brain barrier penetration, survival rates, and resistance inhibition.
The company plans to complete GLP toxicology studies in 2025 and aims to launch clinical studies in early 2026 targeting multiple cancers including GBM, lung, pancreatic, lymphoma, and colorectal cancers.
Theralase Technologies (TLTFF) ha annunciato che presenterà nuove ricerche precliniche sul Rutherrin® attivato dalla radiazione al ASTRO 2025, il 67° Congresso Annuale a San Francisco. Lo studio valuta Rutherrin®, un farmaco a base di rutenio formulato con transferrina umana, confrontandolo con la sola radioterapia nel trattamento del cancro.
La ricerca approfondisce il duplice meccanismo anticancro di Rutherrin: citotossicità immediata tramite la generazione di specie reattive dell'ossigeno e risposta immunitaria prolungata attraverso la morte cellulare immunogenica. Gli aspetti principali che verranno presentati includono il targeting tumorale, la penetrazione della barriera emato-encefalica, i tassi di sopravvivenza e l'inibizione della resistenza.
L'azienda prevede di completare gli studi tossicologici GLP nel 2025 e punta a lanciare studi clinici all'inizio del 2026, mirati a diversi tipi di cancro tra cui GBM, polmone, pancreas, linfoma e colon-retto.
Theralase Technologies (TLTFF) anunció que presentará nueva investigación preclínica sobre Rutherrin® activado por radiación en la ASTRO 2025, la 67ª Reunión Anual en San Francisco. El estudio evalúa Rutherrin®, un fármaco a base de rutenio formulado con transferrina humana, en comparación con la radiación sola para el tratamiento del cáncer.
La investigación explora el doble mecanismo anticancerígeno de Rutherrin: citotoxicidad inmediata mediante la generación de especies reactivas de oxígeno y una respuesta inmunitaria sostenida a través de la muerte celular inmunogénica. Los aspectos clave que se presentarán incluyen la orientación tumoral, la penetración de la barrera hematoencefálica, las tasas de supervivencia y la inhibición de la resistencia.
La compañía planea completar estudios toxicológicos GLP en 2025 y tiene como objetivo lanzar estudios clínicos a principios de 2026 dirigidos a múltiples tipos de cáncer, incluyendo GBM, pulmón, páncreas, linfoma y cáncer colorrectal.
Theralase Technologies (TLTFF)는 샌프란시스코에서 열리는 ASTRO 2025 제67회 연례회의에서 방사선 활성화 Rutherrin®에 관한 새로운 전임상 연구를 발표할 예정입니다. 이 연구는 인간 트랜스페린과 함께 제형화된 루테늄 기반 약물인 Rutherrin®을 단독 방사선 치료와 비교하여 암 치료 효과를 평가합니다.
연구는 Rutherrin의 이중 항암 메커니즘을 탐구합니다: 반응성 산소종 생성에 의한 즉각적인 세포독성과 면역원성 세포사멸을 통한 지속적인 면역 반응입니다. 발표될 주요 내용에는 종양 표적화, 혈액뇌장벽 투과, 생존율, 저항성 억제 등이 포함됩니다.
회사는 2025년에 GLP 독성학 연구를 완료할 계획이며, 2026년 초에 GBM, 폐암, 췌장암, 림프종, 대장암 등 다양한 암을 대상으로 임상 연구를 시작할 예정입니다.
Theralase Technologies (TLTFF) a annoncé qu'elle présentera de nouvelles recherches précliniques sur le Rutherrin® activé par radiation lors de la ASTRO 2025, la 67e réunion annuelle à San Francisco. L'étude évalue Rutherrin®, un médicament à base de ruthénium formulé avec la transferrine humaine, comparé à la radiothérapie seule dans le traitement du cancer.
La recherche explore le double mécanisme anticancéreux de Rutherrin : une cytotoxicité immédiate via la génération d'espèces réactives de l'oxygène et une réponse immunitaire soutenue par la mort cellulaire immunogénique. Les points clés présentés incluent le ciblage tumoral, la pénétration de la barrière hémato-encéphalique, les taux de survie et l'inhibition de la résistance.
L'entreprise prévoit de terminer les études toxicologiques GLP en 2025 et vise à lancer des essais cliniques début 2026, ciblant plusieurs cancers dont le GBM, le poumon, le pancréas, le lymphome et le cancer colorectal.
Theralase Technologies (TLTFF) gab bekannt, dass es neue präklinische Forschung zu strahlenaktiviertem Rutherrin® auf der ASTRO 2025, der 67. Jahrestagung in San Francisco, vorstellen wird. Die Studie bewertet Rutherrin®, ein rutheniumbasiertes Medikament, das mit humanem Transferrin formuliert ist, im Vergleich zur alleinigen Strahlenbehandlung bei der Krebsbehandlung.
Die Forschung untersucht den doppelten krebsbekämpfenden Mechanismus von Rutherrin: sofortige Zytotoxizität durch die Erzeugung reaktiver Sauerstoffspezies und anhaltende Immunantwort durch immunogenen Zelltod. Wichtige Aspekte, die präsentiert werden, umfassen Tumorzielgerichtetheit, Überwindung der Blut-Hirn-Schranke, Überlebensraten und Resistenzhemmung.
Das Unternehmen plant, die GLP-Toxikologiestudien im Jahr 2025 abzuschließen und beabsichtigt, Anfang 2026 klinische Studien zu starten, die sich auf mehrere Krebsarten wie GBM, Lungen-, Pankreas-, Lymphom- und Darmkrebs konzentrieren.
- None.
- None.
Radiation-Activated Rutherrin(R) Versus Radiation Alone in Preclinical Cancer Models to be Presented at ASTRO 2025
This Press Release removes references to preclinical data that has not yet been presented.
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses will present promising new preclinical results at the 2025 American Society for Radiation Oncology ("ASTRO") 67th Annual Meeting. The Company's latest research evaluates radiation-activated Rutherrin® versus radiation alone in the destruction of cancer cells in a number of preclinical cancer models.
This data will be showcased at the 2025 ASTRO 67th Annual Meeting, the world's largest gathering of radiation oncology professionals, taking place in late September in San Francisco, California. ASTRO has selected the Theralase® abstract titled, "Rutherrin® Activated by Radiation Therapy Evaluated for Synergistic Tumor Regression through Direct Destruction and Immune Activation in Multiple Preclinical Cancer Models", for presentation in a scientific poster session.
The study explores the potent anti-cancer effects of Rutherrin®—a ruthenium-based small molecule drug formulated with recombinant human transferrin for intravenous administration. Once activated by ionizing radiation through a process known as Radio Dynamic Therapy ("RDT"), Rutherrin® initiates a two-phase cancer-killing response: the generation of Reactive Oxygen Species ("ROS") for immediate cytotoxicity, followed by Immunogenic Cell Death ("ICD") to stimulate a durable immune response.
The Preclinical Data Presented Will Evaluate:
- Selective Tumor Targeting: Rutherrin®'s accumulation in tumor tissues versus healthy cells.
- Blood-Brain Barrier Penetration: Concentrations in Glio Blastoma Multiforme ("GBM") tumors versus healthy brain tissue.
- Synergistic Mechanism: Combination of direct tumor cell destruction with immune activation.
- Survival Rates: Survival benefits compared to radiation therapy alone.
- Resistance: Inhibition of mechanisms associated with multidrug and radiation resistance.
- Adaptive Immune Activation: Induction of long-term immunity, based on resistance to tumor rechallenge.
Mark Roufaiel, Ph.D., research scientist at Theralase® commented, "Results are expected to be highly encouraging. Rutherrin® is hypothesized to enhance the effectiveness of radiation therapy, but also activate a sustained immune response, offering a powerful, dual-action strategy against aggressive and treatment-resistant cancers."
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase®, added, "Our focus is to bring this innovative platform to clinical application. Rutherrin® may represent a major advancement in oncologic treatment, potentially enabling radiation oncologists to dramatically improve patient outcomes. This research may provide a strong foundation for integrating Rutherrin® with existing cancer therapies to deliver more effective, long-lasting solutions."
Roger DuMoulin-White, B.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase®, stated, "Based on the release of this compelling data in the fall, we are fully committed to completing GLP toxicology studies in 2025. This critical milestone will support the launch of clinical studies in early 2026 targeting GBM, lung, pancreatic, lymphoma and colorectal cancers. We're excited to continue advancing Rutherrin® toward commercialization and transforming cancer care."
About Rutherrin®
Rutherrin® is a patented formulation of Theralase®'s lead ruthenium-based small molecule (Ruvidar®) combined with recombinant human transferrin making it suitable for intravenous delivery. It has the ability to selectively accumulate in cancer cells versus healthy cells and when radiation-activated provide a one-two punch to cancer, by first destroying the cancer cell through oxidative stress and then activating the immune system for destruction of residual cancer cells. Rutherrin® is slated to enter clinical studies in early 2026 for the destruction of deadly cancers; including: brain, lung, pancreatic, colorectal and lymphoma.
About Theralase® Technologies Inc.
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue.
Additional information is available at www.theralase.com and www.sedarplus.ca.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253821
FAQ
What will Theralase Technologies (TLTFF) present at ASTRO 2025?
How does Theralase's Rutherrin® work in cancer treatment?
What are Theralase's (TLTFF) clinical development plans for Rutherrin®?
When and where will the ASTRO 2025 conference take place?
